Abstract Number: 2392 • 2018 ACR/ARHP Annual Meeting
Are Single Nucleotide Polymorphisms in Methotrexate Transporter Proteins Associated with Methotrexate Intolerance in Juvenile Idiopathic Arthritis?
Background/Purpose: Methotrexate (MTX) intolerance is common in juvenile idiopathic arthritis (JIA) and poses the risk of premature termination of an effective treatment. MTX intolerance is…Abstract Number: 2393 • 2018 ACR/ARHP Annual Meeting
Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?
Background/Purpose: Nausea to low-dose methotrexate (MTX) is a significant clinical challenge in the treatment of juvenile idiopathic arthritis (JIA). There exists a large inter-individual variation…Abstract Number: 34 • 2017 Pediatric Rheumatology Symposium
The SLCO1B1 *14 Allele is Associated with Poor Response to Subcutaneous Methotrexate in Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Variants in the SLCO1B1 gene, encoding a hepatic methotrexate (MTX) transporter, affect clearance of high-dose MTX in leukemia patients. We aimed to assess the…Abstract Number: 3008 • 2016 ACR/ARHP Annual Meeting
Clinical Factors Associated with Non-Response to Methotrexate in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Response to Treatment Consortium
Background/Purpose: Although the recommended first line treatment for JIA, up to 50% of children will not respond to MTX. Currently, it is not possibly to…Abstract Number: 3009 • 2016 ACR/ARHP Annual Meeting
Safety and Effectiveness of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common chronic inflammatory rheumatic diseases of childhood. Due to their long-term safety and efficacy, biologic disease modifying…Abstract Number: 296 • 2014 ACR/ARHP Annual Meeting
Countermeasures Against Methotrexate Intolerance in Juvenile Idiopathic Arthritis Instituted By Parents Show No Effect
Background/Purpose: Methotrexate (MTX) is the mainstay treatment in the therapy of children with juvenile idiopathic arthritis (JIA) and can lead to prolonged remission and improved…Abstract Number: 299 • 2014 ACR/ARHP Annual Meeting
A Controlled Trial of Intra-Articular Corticosteroids with or without Methotrexate in Oligoarticular Juvenile Idiopathic Arthritis
Background/Purpose In contrast with the numerous randomized controlled trials conducted in polyarticular or systemic juvenile idiopathic arthritis (JIA), little evidence-based information is available for oligoarticular…Abstract Number: 312 • 2014 ACR/ARHP Annual Meeting
Mutations in the MTHFR Gene Are Not Associated with Methotrexate Intolerance in Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Methotrexate (MTX) is the drug used most frequently in the therapy of juvenile idiopathic arthritis (JIA). However, long-term treatment in children frequently leads…Abstract Number: 792 • 2013 ACR/ARHP Annual Meeting
Methotrexate Polyglutamates in Erythrocytes Are Associated With Lower Disease Activity in Juvenile Idiopathic Arthritis Patients
Background/Purpose: Methotrexate polyglutamates (MTX-PG) could be biomarkers of MTX response and adverse effects and could thus be used as a therapeutic drug monitoring (TDM) tool to steer tailor-made therapeutic…Abstract Number: 297 • 2013 ACR/ARHP Annual Meeting
Plasma Nicotinamide Phosphoribosyltransferase Correlates With Markers Of Inflammation and May Predict Early Therapeutic Response To Low-Dose Methotrexate In Juvenile Idiopathic Arthritis
Background/Purpose: Despite a poor understanding of its biochemical role in the inflammatory process, nicotinamide phosphoribosyltransferase (NAMPT) has been implicated in a number of autoimmune…Abstract Number: 268 • 2013 ACR/ARHP Annual Meeting
Inflammatory Bowel Disease In Juvenile Idiopathic Arthritis Patients Upon Biologics
Background/Purpose: Inflammatory bowel disease (IBD) is a matter of interest in patients with juvenile idiopathic arthritis (JIA) treated with biologics. Methods: Baseline demografics, clinical characteristics…Abstract Number: 1159 • 2012 ACR/ARHP Annual Meeting
Reasons and Predictors of Methotrexate Discontinuation in Children with JIA: Results From the Childhood Arthritis Prospective Study (CAPS)
Background/Purpose: Methotrexate (MTX) is the DMARD of first choice in patients with juvenile idiopathic arthritis (JIA). However, limited data is available on MTX survival, including…Abstract Number: 1146 • 2012 ACR/ARHP Annual Meeting
Choice of Systemic JIA Treatment Among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists
Background/Purpose: Despite recent advances in identifying effective treatments for systemic Juvenile Idiopathic Arthritis (sJIA), many pediatric rheumatologists continue to use corticosteroids and methotrexate. The Childhood…Abstract Number: 2654 • 2012 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Methotrexate Response Identifies Novel Genes in a Large Cohort of European Juvenile Idiopathic Arthritis Cases
Background/Purpose: The drug methotrexate (MTX) is the first line treatment for many children with Juvenile Idiopathic Arthritis (JIA). Only 45% of children treated with MTX…
ACR Meeting Abstracts